Ryzodeg 100IU/ml Flextouch Pen 3 ml belongs to the class of medications called ‘antidiabetics’ primarily used for the treatment of both type 1 and type 2 diabetes mellitus. Ryzodeg 100IU/ml Flextouch Pen 3 ml is a combination of two drugs, namely, Insulin Aspart and Insulin Degludec. Ryzodeg 100IU/ml Flextouch Pen 3 ml contains insulin aspart, which is a fast-acting form of insulin that helps lower blood sugar levels after food intake. Ryzodeg 100IU/ml Flextouch Pen 3 ml contains insulin degludec, which is a prolonged action form of insulin. It typically begins working after 60 minutes and is a long-acting insulin preparation (lasts for more than 24 hours). Together, they confirm rapid and stable sugar control by helping reuptake sugar in fat and muscle, and cells and suppressing the creation of sugar in the liver. 

Ryzodeg 100IU/ml Flextouch Pen 3 ml should be administered subcutaneously (in the upper thigh, abdomen, upper arm, or buttocks). If you are not trained to self-administer Ryzodeg 100IU/ml Flextouch Pen 3 ml, ask your healthcare professional to administer it.

• Rashes
• Injection site allergic reaction
• Weight gain
• Edema (swelling)
• Lipodystrophy (skin thickening or pits at the injection site)
• Hypoglycemia (low blood glucose level)
• Itching

Store in a cool and dry place away from sunlight